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Abstract: Pyropheophorbide a (Pyro) is a near-infrared (NIR) fluorescent dye and photosensitizer with high quantum 
yield that makes the dye suitable for tumor treatment both as an imaging and therapy agent. We have designed 
and synthesized a series of a Pyro-based NIR probes, based on the conjugation of Pyro with lipids. The nature of 
our probes requires the use of a lipophilic carrier to deliver the probes to cancer cell membranes. To address this, 
we have utilized lipid-based nanoparticles (LNPs) consisting of PEGylated lipids, which form the nanoparticle shell, 
and a lipid core. To endow the LNPs with targeting properties, nitrilotriacetic acid (NTA) lipids were included in 
the composition that enables the non-covalent attachment of His-tag targeting proteins preserving their functional 
activity. We found that the nature of the core molecules influence the nanoparticle size, shelf-life and stability at 
physiological temperature. Two different Pyro-lipid conjugates were loaded either into the core or shell of the LNPs. 
The conjugates revealed differential ability to be accumulated in the cell membrane of the target cells with time. 
Thus, the modular organization of the core-shell LNPs allows facile adjustment of their composition with goal to fine 
tuning the nanoparticle properties for in vivo application.
Keywords: Lipid-based nanoparticles, near-infrared fluorescent probes, lipid-based fluorescent imaging agent, 
pyropheophorbide a
Introduction
Near-infrared (NIR) dyes are advantageous for 
bioimaging because the fluorescence of NIR 
chromophores allows for high tissue penetra-
tion (millimeters to centimeters deep) and does 
not overlap with tissue autofluorescence [1, 2]. 
NIR fluorescence does not involve ionizing radi-
ation, requires only relatively low-cost detec-
tion systems, and can be utilized not only for 
imaging but also for photodynamic therapy 
(PDT). We have recently developed a series of 
NIR fluorescent imaging probes based on the 
NIR dye pyropheophorbide a (Pyro) [3-5]. Pyro 
possesses both NIR fluorescent [3-5] and pho-
toreactive [6, 7] properties. The probes were 
constructed by conjugation of the Pyro moiety 
with a phospholipid backbone [3]. One of them, 
Pyro-phosphatidylethanolamine (Pyro-PtdEtn) 
is shown in Figure 1. This phospholipid conju-
gate and other hydrophobic conjugates of Pyro, 
such as Pyro-cholesterol oleate (Pyro-CE-OA) 
[8] (Figure 2), cannot be solubilized in aqueous 
solution. Therefore, the application of these NIR 
probes as well as many other NIR dyes are ham-
pered by their hydrophobicity, and methods of 
probe delivery have to be developed. The most 
advantageous way to deliver a hydrophobic 
probe to a disease site in vivo is to utilize a lipid-
based nanoparticle platform. Compared to 
other nanocarriers, lipid-based nanoparticles 
are distinguished by their self-assembled struc-
ture and are biodegradable. Several lipid-based 
nanocarrier formulations are already approved 
for clinical applications [9-12].
One approach to develop a lipid-based nano-
platform for the delivery of lipophilic NIR probes 
is to use lipoproteins, naturally occurring nano- 
particles that are present in the human body 
and play an essential role in transport and con-
trol of lipid metabolism. Low-density lipoprotein 
(LDL) is the most commonly used nanolipopro-
tein. LDL consists of a phospholipid monolayer, 
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shell containing apolipoproteins and a hydro-
phobic lipid core containing cholesterol esters 
and triglycerides. These natural nanoparticles 
are stable in the blood circulation and have a 
size (<30 nm) appropriate for avoiding the retic-
uloendothelial system. Such lipoprotein nano-
platforms have been used as a delivery vehicle 
for a number of lipophilic drugs and imaging 
agents [13-15]. A major problem to this 
approach is the existence of receptors recog-
nizing apolipoproteins in different human tis-
sues leading to high background binding. To 
overcome this drawback, we developed core-
based lipid nanoparticles (LNPs) with the struc-
ture mimicking the core-shell organization of 
natural lipoproteins. Metal-ion-chelating lipids 
were included into the shell for conjugation with 
targeting proteins. We varied the LNP core com-
position, NIR lipid probe structure, and the 
nature of the targeting moiety in order to inves-
tigate the LNP properties as a universal multi-
modal lipid-based nanocarrier for delivery of 
hydrophobic NIR dyes.
Materials and methods
Reagents
DSPE-PEG (1,2-distearoyl-sn-glycero-3-phosph- 
oethanolamine-N-[methoxy (polyethylene gly-
col) -750], ammonium salt), DOGS-NTA (1,2-dio-
leoyl-sn-glycero-3-((N(5-amino-1-carboxypen-
tyl)iminodiacetic acid) succinyl), ammonium 
salt) and N-BOC Lyso PtdEtn (N-Boc16:0 Lyso 
PE) were purchased from Avanti Polar Lipids, 
Inc., Alabaster, AL, USA. Cholesterol oleate (CE-
OA) was purchased from Sigma Aldrich. Fluo-3 
was purchased from Life Technologies, Grand 
Island, NY USA. Spirulina pacifica algae (the 
starting material for Pyro) was purchased from 
Sigma-Aldrich and used without further purifi-
cation. Pyropheophorbide-a acid (Pyro) and 
5-Androsten-17β-Boc-amino-3β-yl Oleate (BOC-
CE-OA) were synthesized according to [8]. 1-pal-
mitoyl-2-pyropheophorbide-sn-glycero-3-phos-
phoethanolamine (Pyro-PtdEtn) was prepared 
as previously described [3].
Spectral methods
1H NMR spectra were recorded using Bruker 
DMX 360 MHz and DRX 500 MHz spectrome-
ters. MALDI-TOF mass-spectra were recorded 
with an Applied Biosystems Voyager DE Mass 
Spectrometer using a positive mode ionization 
and CHCA (α-cyano-4-hydroxycinnamic acid) or 
HABA (2-(4-hydroxyphenylazo)benzoic acid) ma- 
trix.
Cells 
The Epstein-Barr virus (EBV)-transformed B- 
cell line JY (HLA-A2, B7, Cw7) was grown in 
RPMI-1640 medium containing 10% fetal calf 
serum, 10 mM HEPES, 2 mM L-glutamine, 100 
U/ml penicillin, 100 µg/ml streptomycin and 50 
µM β-mercaptoethanol (R10). The human Flu-
specific CTL clone CER43 that recognizes the 
matrix protein peptide GILGFVFTL (GL9) in 
association with HLA-A2 MHC class I protein 
[16], was kindly provided by A. Lanzavecchia 
and was maintained in culture, as previously des- 
cribed [17, 18]. 
Synthesis
We developed a new two-step synthesis of 
5-androsten-17β-pyropheophorbide-amino-3β-
yl oleate (Pyro-CE-OA) (Figure 2). This synthetic 
pathway is described in the Results section.
Figure 1. 1-palmitoyl-2-pyropheophorbide-sn-glycero-3-phosphatidylethanola- 
mine (Pyro-PtdEtn).
Cyanotech Corporation, Ka- 
ilua-Kona, HI, USA. 5-Andr- 
osten-17β-amino-3β-ol was 
purchased from Steraloid 
Inc., Newport, RI. Silica Gel 
Standard Grade (230x450 
mesh) was purchased from 
Sorbent Technologies, Atlan- 
ta, GA, USA. Solvents were 
purchased from Fisher Sci- 
entific; dry solvents were pu- 
rchased from ACROS Orga- 
nics. Other reagents/reac-
tants were purchased from 
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5-Androsten-17β-Pyropheophorbide-amino-3β-
ol (Pyro-CE) 
The synthesis scheme is presented in Figure 2. 
Pyropheophorbide a acid (Pyro, 103.0 mg, 
0.193 mmol), N-hydroxysuccinimide (22.3 mg, 
0.193 mmol), EDC (36.9 mg, 0.193 mmol), 
DMAP (5.8 mg, 0.048 mmol) and dry DCM (50 
mL) were placed into a 100 mL round bottom 
flask (RBF) equipped with a magnetic stirring 
bar. The reaction mixture was stirred for 10 h in 
the dark under argon at room temperature. The 
reaction was monitored by thin layer chroma-
tography (TLC; EtOAc/CHCl3 1/1, v/v) until total 
Pyro conversion into Pyro-SU ester was 
observed. Then 5-androsten-17β-amino-3β-ol 
(50 mg, 0.193 mmol) and 2 mL pyridine were 
added into the flask. The reaction mixture was 
agitated for more 20 h in dark under argon at 
room temperature. The volatiles were evapo-
rated and the dark green product was isolated 
by column chromatography (DCM/EtOAc/MeOH 
1/1/0-0.1, v/v/v) in 96% yield (149.3 mg). TLC: 
one spot, Rf=0.15 EtOAc/CHCl3 1/5, v/v. 
1H 
MNR (500 MHz, DMSO-d6, δ): 10.19 (bs, 1H, CE 
(c) c3-βOH), 9.57, 9.38 and 8.76 (each s, 1H, 
pyro (p) p5-H, p10-H, p20-H), 8.08 (dd, J=11.6 
Hz, J=17.8 Hz, 1H, p31-CH=CH2), 7.33 (d, J=8.6 
Hz, 1H, c6-H), 6.31 (d, J=17.8 Hz, 1H, trans-
p32-CH=CHH), 6.18 (d, J=11.6 Hz, 1H, cis-p32-
CH=CHH), 5.18 (s, 1H, c20-βNH), 5.13 (AB, 
A=5.23, B=5.03, JAB=19.7 Hz, 2H, p13
2-CH2), 
4.59 (q, J=7.3 Hz, 1H, p18-H), 4.28 (dm, J=8.6 
Hz, 1H, p17-H), 3.71 (q, J=7.4 Hz, 2H, p81-CH2), 
3.66 (m, 1H, c3-αH), 3.60, 3.42, 3.19, (each s, 
3H, p21-CH3, p7
1-CH3, p12
1-CH3), 3.24 (m, 1H, 
c17-αH), 2.67-2.33 (overlap with the solvent 
signal, m, 4H, p171-CH2 and c4-CH2), 2.23-1.93 
(m, 4H, p172-CH2 and c7-CH2), 1.84-0.78 (multi-
plets, 15H, c1-CH2, c2-CH2, c10-CH, c11-CH2, 
c12-CH2, c13-CH, c14-CH, c15-CH2, c16-CH2) 
1.81 (d, J=7.3 Hz, 3H, p18-CH3), 1.63 (t, J=7.4 
Hz, 3H, p82-CH3), 0.85 (s, 3H, c19-CH3), 0.46 (s, 
3H, c18-CH3), -1.75 (s, 2H, p21-NH and p23-
NH). MALDI-TOF, m/z: (M+Na)+ 828.55, calcu-
lated for C52H63N5NaO3 828.48 (see Supporting 
Information, SI).
5-Androsten-17β-pyropheophorbide-amino-3β-
yl oleate (Pyro-CE-OA)
Pyro-CE (120 mg, 0.149 mmol) was dissolved 
in dry pyridine 50 mL (100 mL RBF), and oleoyl 
chloride (250 mg, 0.831 mmol) was added. The 
reaction mixture was agitated for 6 h at room 
Figure 2. Synthesis of 5-Androsten-17β-
pyropheophorbide-amino-3β-yl oleate (Py- 
ro-CE-OA).
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temperature in the dark under argon gas. The 
volatiles were evaporated; the remainder was 
dissolved in chloroform and washed with 0.1 N 
HCl, followed by 2 times with DI water. The solu-
tion was dried over anhydrous Na2SO4. The 
product was isolated by column chromatogra-
phy (hexanes/EtOAc 1->0/0->1 v/v, Vhexanes+ 
VEtOAc=1) in 82.3% yield (131.3 mg). TLC: one 
spot, Rf=0.4, EtOAc/CHCl3 1/5, v/v.
1H NMR (360 MHz, CDCl3/CD3OD, δ): 9.18, 
9.06, and 8.41 (each s, 1H, pyro (p), p5-H, p10-
H, and p20-H); 7.78 (dd, J=17.8 Hz, J=11.6 Hz, 
1H, p31-CH=CH2); 7.14 (d, J=8.6 Hz, 1H, CE (c) 
c6-H), 6.12 (d, J=17.8 Hz, 1H, trans-p32-
CH=CHH); 6.02 (d, J=11.6 Hz, 1H, cis-p32-
CH=CHH); 5.20 (m, 2H, oleate (o) o9-H and 
o10-H, CH=CH), 5.06 (AB, A=5.14, B=4.99, 
JAB=19.9 Hz, 2H, p13
2-CH2); 4.36 (qd, J=7.3 Hz, 
J=1.7 Hz 1H, p18-H) 4.17 (m, 2H, p17-H and 
c3-αH); 3.74 (m, 1H, c17-αH, overlapped with 
the solvent signal), 3.47, 3.26 and 3.99 (each s, 
3H, p21-CH3, p7
1-CH3 and p12
1-CH3 ), 3.63 (q, 
J=7.7 Hz, 2H, p81-CH2CH3), 2.65-2.10 (m, 12H, 
p171-CH2, p17
2-CH2, o8-CH2, o11-CH2, c4-CH2 
and c7-CH2), 2.09-0.83 (m, 39H, o2-CH2, 
o3-CH2, o4-CH2, o5-CH2, o6-CH2, o7-CH2, o12-
CH2, o13-CH2, o14-CH2, o15-CH2, o16-CH2, 
o17-CH2, c1-CH2, c2-CH2, c11-CH2, c12-CH2, 
c15-CH2, c16-CH2, c8-CH, c9-CH, c14-CH), 
1.72 (d, J=7.3 Hz, 3H, p181-CH3CH); 1.52 (t, 
J=7.7 Hz, 3H, p82-CH3CH2), 0.80 (m, 6H, c19-
CH3 and o18-CH3), 0.35 (s, 3H, c18-CH3). 
MALDI-TOF, m/z: (M+Na)+ 1093.05, calculated 
for C70H95N5NaO4 1092.73 (see SI).
Protein expression and purification 
Soluble HLA-A2 protein was expressed in S2 
cells and “empty” HLA-A2 protein molecules 
were purified from the culture supernatant as 
previously described [19, 20]. Soluble HLA-A2 
molecules (3-5 mg/ml) were loaded with the 
peptide of interest overnight at 23-25°C at sat-
urating peptide concentration (10-4-10-5 M). HIV 
RT-derived peptide ILKEPVHGV (IV9) was a gen-
erous gift from Herman Eisen (Massachusetts 
Institute of Technology). GILGFVFTL (GL9) pep-
tide from the matrix protein of influenza virus 
was synthesized by Research Genetics 
(Huntsville, AL). The GL9-HLA-A2 complex spe-
cifically interacts with the T cell receptor on the 
surface of the CER-43 CD8 T cell clone, while 
the IV9-HLA-A2 does not [19, 20]. cDNA coding 
Figure 3. Schematic structure of LNP. PEGylated lipids regulate the solubility of LNPs in water solutions. Metal 
chelating groups are used for binding protein via a His6 tag. The His6 tag controls the protein ligand binding site 
orientation allowing the attachment of protein molecules without any chemical modification. The Pyro molecules 
are conjugated to cholesterol or to glycerol based lipids. Fluorescent properties of the molecule will allow in vivo 
molecular imaging and photodynamic therapy. The lipid core composition has influence on the stability of the LNPs. 
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human ICAM-1 protein was cloned from JY 
cells. Soluble recombinant human ICAM-1 pro-
tein containing a His6-tag on the C-end of the 
molecule was produced in the Drosophila cell 
system and purified by affinity chromatography 
using monoclonal antibody against human 
ICAM-1 (HB9580, ATCC) as previously described 
[19, 20]. Protein labeling with Cy5 fluorescent 
dye was performed according to manufactur-
er’s instructions (Amersham, GE Healthcare). 
After the labeling procedure the protein was 
subjected to affinity chromatography on Ni-NTA 
Agarose (QIAGEN). 
LNP preparation
The core components (CE-OA or BOC-CE-OA or 
cholesterol), DSPE-PEG and DOGS-NTA in dried 
chloroform were mixed at a molar ratio of 
12:68:20. In some cases, fluorescent lipids 
were added as indicated. Chloroform was re- 
moved with an argon stream and the lipid film 
was additionally dried under vacuum for 3 
hours. Lipids were hydrated under argon with 
intermittant vortexing in hot (65-80°C) HEPES 
buffered saline (10 mM HEPES, 140 mM NaCl) 
at a total lipid concentration of 5 mM. The mix-
ture was cooled down in a water bath to room 
temperature. The suspension was filtered th- 
rough 0.2 μm mini filters (Sterlitech) and kept 
under argon at 4°C. To load the NTA moiety with 
nickel ions, NiSO4 solution was added to the 
LNPs at a final concentration of 100 mM. After 
30 min of incubation, unbound Ni2+ ions were 
removed by gel filtration on a Bio-Rad mini col-
umn loaded with HBS buffer. 
To make fluorescently labeled lipid nanoparti-
cles we used either Pyro-CE-OA or Pyro-PtdEtn 
lipids. Before the assembly of the nanoparti-
cles each fluorescent conjugate was dissolved 
in chloroform, and the absorption of the solu-
tion was measured at 410 nm. Using the extinc-
tion coefficient for Pyro (e=110,000 M-1cm-1), 
[3] we were able to calculate the concentration 
of the Pyro-lipid conjugate solutions. To avoid 
self-quenching of the probes, we included only 
3% mol of fluorescent molecules into the LNP 
composition [4].
Light scattering
The size distributions of the LNPs were mea-
sured by light-scattering photon correlation spe- 
Figure 4. Size distribution of the LNPs (A) with Boc modified cholesterol oleate (BOC-CE-OA) core, (B) without core, 
(C) with cholesterol oleate core, and (D) with cholesterol core as measured by dynamic light scattering. The structure 
of corresponding LNP core components are shown on the right side of the Figure. 
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ctroscopy (Zetasizer 3000HS, Malvern Ins- 
truments, Malvern, UK) utilizing a 10-mW He- 
Ne laser operating at 633 nm and a detector 
angle of 90°. The data were modeled assuming 
spherical particles undergoing Brownian mo- 
tion [21].
Conjugation of Ni-NTA-LNPs with protein 
ligands
Conjugate formation was driven by self-assem-
bly between His6-terminated proteins and LNPs 
functionalized with Ni-NTA-DOGS lipids as has 
been described elsewhere [22, 23]. Ni-NTA-
LNPs were mixed with protein ligand solution. 
The mixture was incubated at room tempera-
ture for 10 min and diluted with DPBS contain-
ing 1% BSA to required ligand concentration.
Agarose gel electrophoresis
LNPs and Cy5 labelled HLA-A2 protein (3 mg/
ml) were mixed at ratios 5:1 and 1:1 (v/v) and 
bands. The lipid bands were visualized by stain-
ing with Sudan Black B as recommended by the 
Paragon electrophoresis kit manufacturer. Ele- 
ctrophoretic mobility of the protein bands was 
compared with electrophoretic mobility of 
bands stained with the lipid dye. 
Flow cytometry analysis
Binding of LNPs/protein conjugates to the sur-
face of live cells was evaluated by flow cytome-
try as previously described [22, 23]. 2x105 
CER-43 cells were washed with FACS buffer 
(DPBS/1% BSA with or without Ca2+ and Mg2+ 
as indicated) and suspended in the buffer con-
taining different concentration of protein ligand 
conjugated with fluorescent LNPs. Control cells 
were loaded with unconjugated LNPs. In some 
experiments fluorescent LNPs containing the 
NTA lipid moiety without Ni2+ were utilized as an 
additional control. The staining procedure was 
performed at 4°C or 37°C for the indicated 
time interval. The cells were washed with the 
Figure 5. Agarose gel electrophoresis of LNPs. (A) LNPs with cholesterol 
oleate core were conjugated with Alexa647 labelled pMHC at ratio 5:1 and 
1:1 (v/v) as described in the Materials and Methods: unconjugated pMHC-
Alexa647 (first line), pMHC-Alexa647 conjugated with LNPs at ratio 1:5 
(v/v) (second line), and pMHC-Alexa647 conjugated with LNPs at ratio 1:1 
(v/v) (third line). (B) LNPs with cholesterol oleate core were conjugated with 
unlabeled pMHC and were subjected to electrophoresis using the Paragon 
electrophoresis kit. The gel was consequently stained with Paragon lipid 
stain and with Coomassie blue.
incubated at room temperature 
for 30 min. The samples were 
mixed with 3% glycerol TBE 
loading buffer (10 mM Tris-
borate with 2 mM EDTA, pH 
8.5) immediately prior to use. Un- 
conjugated labeled protein was 
used as a control. A 15 V/cm 
electric field was applied to a 
1% agarose gel for 20 min. The 
protein bands were detected by 
light absorption.
The lipid component of the 
ICAM-1-LNP conjugate was de- 
termined by electrophoresis 
performed on 0.5% agarose gel 
(Beckman, Paragon Lipo Kit). 
The conjugated ICAM-1-LNP 
samples (1:5 v/v) were subject 
to electrophoresis in barbital 
buffer from the kit. After elec-
trophoresis, the gels were fixed 
in a solution of ethanol-acetic 
acid-water 60:10:30 (v/v/v) 
and then stained (5 min) with a 
0.15% Coomassie Blue R250 
solution. Gels were destained 
in a solution of methanol-acetic 
acid-water 35:25:40 (v/v/v) 
until the Coomassie Blue stains 
disappeared from the gel 
Core-based lipid nanoparticles
513 Am J Nucl Med Mol Imaging 2014;4(6):507-524
buffer, and the samples were analyzed on an 
Epics XL-MCL flow cytometer (Beckman Coulter, 
Fullerton, CA) with fluorescence excitation at 
633 nm and emission at 675 nm. 
Ca2+ flux measurements
Measurements of Ca2+ flux elicited by specific 
binding of LNP/pMHC conjugates to CTL sur-
face was performed as described elsewhere 
[22, 23]. Briefly, CER-43 cells (107 cells/ml) 
were loaded with Fluo-3 Ca2+ sensitive fluoro-
phore as previously described. The cells were 
washed free of unreacted dye and resuspend-
ed in assay buffer (DPBS containing 1 mM 
CaCl2, 0.1 mM MgCl2, 5 mM glucose and 
0.025% BSA) at 106 cells/ml. Freshly prepared 
LNPs conjugated with pMHC were promptly 
added to 1 ml of the cell suspension. The sam-
ples were analyzed on a Coulter Epics XL-MCL 
flow cytometer. The data collection was initiat-
ed as soon as possible following the back-
ground measurements. The data were analyzed 
with FlowJo software. Unloaded LNPs and cog-
nate pMHC complex mixed with LNPs contain-
ing NTA lipid moiety without Ni2+ were utilized as 
negative controls.
Microscopy 
LNPs loaded with Pyro-PtdEtn fluorophore were 
used for microscopy analysis. CER-43 cells 
were stained with fluorescent LNP/pMHC con-
Synthesis of Pyro-CE-OA 
We have developed a novel two-step synthesis 
of 5-Androsten-17β-pyropheophorbide-amino-
3β-yl oleate (Pyro-CE-OA). This synthetic path-
way is presented in Figure 2. A previously 
described preparation [8] included 1) Boc-
protection of the amino group of CE, 2) O- 
acylation with oleoyl chloride, 3) TFA-mediated 
Boc-deprotection; 4) conversion of the obtained 
CE-OA trifluoroacetic salt into a free amine with 
NaHCO3 and 5) Pyro-acid activation with 1- 
hydroxybenzotriazole followed by a coupling 
with the CE-OA. The final product was isolated 
by preparative TLC. That procedure afforded 
several milligrams of the target product with 
the overall yield 10%. Our new procedure 
included 1) a one-pot synthesis of Pyro-SU 
ester (Pyro, NHS, DMAP) followed by a coupling 
with amino group of CE (5-androsten-17β-
amino-3β-ol) and 2) O-acylation with oleoyl 
chloride. The intermediate and final products 
were isolated with preparative column chroma-
tography with the overall yield 79% (relative to 
CE). This new approach affords hundreds of 
milligrams of Pyro-CE-OA.
Design and assembly of LNPs
The PEG-phosphatidylethanolamine (PEG-Ptd- 
Etn) conjugate was chosen as a major constitu-
ent of the LNP shell (Figure 3). It has been 
shown that a phospholipid/PEG-PtdEtn mixture 
Figure 6. Time-dependent changes in intracellular calcium concentration in 
CD8+ CER43 T cells induced by GL9-HLA-A2 ligands assembled on either LNPs 
(bold black) or lipid encapsulated QDs (bold grey) scaffolds. Unloaded LNPs (thin 
black) and cognate pMHC complex mixed with LNPs containing NTA lipid moiety 
without Ni2+ (thin grey) were utilized as negative controls. The concentration of 
the pHLA-A2 in the extracellular medium was 100 nM. The mean fluorescent 
intensity of the cells over time was measured by flow cytometry. 
jugates for 3 hr at 37°C. 
After the washing proce-
dure the cells were resus-
pended in 100 µl DPBS/1% 
BSA with Ca2+ and Mg2+ 
and placed in 96-well pla- 
tes with slide glass bot-
tom. The cell fluorescence 
was analyzed using a wide-
field epifluorescence Zeiss 
Axiovert 200 M inverted 
microscope with a Roper 
CoolSnap HQ CCD mono-
chrome camera. The cell 
samples were excited by 
the Xenon Lamp at 620/60 
nm and the 700/75 nm 
band pass filter was uti-
lized for emission. 
Results 
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forms stable micelles when the PEG-PtdEtn 
content exceeds a critical limit [24-26]. For the 
particular mixture of PEG-PtdEtn and NTA-
DOGS lipid that was utilized in the present 
research, the molar content of PEG-PtdEtn lipid 
should be greater than 60% mol [23, 27], so 
67-77% mol of PEG-PtdEtn lipids were used in 
the LNP formulation. Small variations in the 
PEG-PtdEtn molar content depend on the quan-
tity of all other components employed in the 
LNP composition. 
Micelles prepared from PEG-PtdEtn lipids can 
be loaded with various hydrophobic inorganic 
Figure 7. (A) Relative amplitudes of calcium influx induced in CD8+ CER43 T cells by Pyro-LNPs-GL9-HLA-A2 conju-
gates with different cores. The LNPs were pre-incubated at 37°C in DPBS/1% BSA for the indicated time. Mean±SD 
are calculated at plateau of the curves (200-250 s), (*)=p<0.01. (B) Time-dependent changes in intracellular cal-
cium concentration in CD8+ CER43 T cells induced by Pyro-LNPs-GL9-HLA-A2 conjugate with cholesterol oleate core 
after preincubation of the LNPs for indicated time at 37°C. The concentration of the pHLA-A2 in extracellular me-
dium was 100 nM. The mean fluorescent intensity of the cells over time was measured by flow cytometry. (C) Binding 
of the Pyro-LNPs-GL9-HLA-A2 conjugates with different core to the surface of CER43 T cells. The LNPs conjugates 
were pre-incubated at 37°C for 3 hours in DPBS/1% BSA. The concentration of the pHLA-A2 in extracellular medium 
was 2 μM. The mean fluorescent intensities of the stained cells were measured by flow cytometry.
Figure 8. Binding of ICAM-1-LNP-Pyro-PtdEtn to CD8+ CER43 T cells expressing cell surface αLβ2 integrins that recog-
nize ICAM-1. The cells were incubated with the LNPs conjugate in the presence (A) or absence (B) of Ca2+ and Mg2+ 
in the staining buffer. Cells incubated with plain LNPs, i.e., untargeted nanoparticles (grey) were used as negative 
control. The mean fluorescent intensity of the cells was measured by flow cytometry. Fluorescence was excited at 
633 nm and emission collected at 675 nm. (C) The dependence of ICAM-1-NP-Pyro-PtdEtn binding to CER-43 cells 
on ICAM-1 concentration is shown. Cells incubated with untargeted nanoparticles were utilized as a negative con-
trol. Mean±SD is shown, (*)=p<0.05.
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compounds of defined size such as quantum 
dots (QDs), a semiconductor nanocrystal [28-
31]. The inorganic core significantly increases 
stability of the particles. Natural high-density 
lipoproteins have sizes similar to PEG-PtdEtn 
micelles and contain a hydrophobic lipid core 
consisting mostly of various cholesterol esters 
and triglycerides. To study how the nature of 
the core influences LNP stability and size, we 
designed and assembled LNPs with different 
core lipids: (i) cholesterol (CE); (ii) cholesterol 
oleate (CE-OA); (iii) N-BOC-protected amino cho-
lesterol oleate (BOC-CE-OA). Based on the 
structure of high-density lipoprotein, we esti-
mate that core lipids should be around 10-15% 
mol of total lipid to completely fill the interior 
LNP space [32, 33]. When the content of the 
core lipids was increased, lipid precipitation 
was observed indicating that the nanoparticle 
core can accommodate a limited amount of 
cholesterol ester molecules.
To enhance NIR probe delivery to a particular 
cell type, LNPs should be modified with target-
Figure 9. Binding of (A) ICAM-1-LNP-Pyro-PtdEtn and (B) ICAM-1-LNP-Pyro-CE-OA to CD8+ CER43 T cells. Binding of 
the LNPs loaded with irrelevant pHLA-DRB1 protein is shown with grey line. Cells incubated with plain LNPs, i.e., 
untargeted nanoparticles (grey) were used as negative control. (C and D) Time course of ICAM-1-LNPs (black) bind-
ing to CD8+ CER43 T cells. CER-43 cells were incubated in the presence of (C) ICAM-1-LNP-Pyro-PtdEtn or (D) ICAM-
1-LNP-Pyro-CE-OA for 30 min to 24 h. Cells incubated with untargeted LNPs (grey) were used as negative control. 
After exhaustive washing, the cells were analyzed by flow cytometry. Mean±SD is shown, (*)=p<0.05. The mean 
fluorescent intensity of the cells was measured by flow cytometry. Fluorescence was excited at 633 nm with emis-
sion at 675 nm.
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ing ligands. To functionalize the LNPs, metal-
chelating lipids (Ni-NTA-DOGS) were included in 
the particle composition. The Ni-NTA moiety 
allows conjugation with protein molecules con-
taining polyhistidine-tags. To maximize the den-
sity of metal chelating groups, 20% of DOGS-
NTA containing lipids were used in the LNP 
formulation. This density of Ni-NTA moieties inc- 
reases the strength of interaction between 
His6-tagged protein molecules and Ni-NTA 
groups [34]. Previously we successfully utilized 
a similar approach for functionalizing PEG-
PtdEtn micelle with inorganic core [23, 27].
The lipid-conjugated fluorochromes were intro-
duced into either the core or shell lipids of the 
LNPs. All fluorescent probes were based on the 
neutral fluorophore Pyro as a fluorescent probe 
and photosensitizer with high 1O2 quantum 
yield [35]. Pyro has a far red excitation at 670 
nm with near infrared emission at 720 nm that 
permits increased penetration into tissues. 
This allows the utilization of the probes in vivo 
for imaging [4] and the potential for killing 
unwanted cells by photodynamic therapy (PDT). 
The two various lipid based NIR fluorescent 
probes were synthesized: (i) Pyro-CE-OA (Figure 
2) and (ii) Pyro-PtdEtn (Figure 1). Pyro-CE-OA 
contains a cholesterol oleate moiety designed 
to be incorporated into the LNP core. The Pyro-
PtdEtn probe was constructed by conjugation 
of Pyro to the PtdEtn backbone at the sn-2 posi-
tion of the glycerol backbone in order to be 
included in LNP shell. 
Dependence of LNP size on core composition
The chosen core molecules are distinct from 
each other by hydrophobicity, conformational 
flexibility and the ability to form hydrogen 
bonds. The cholesterol molecules are the most 
rigid structures. The cholesterol molecules are 
able to intercalate between the lipids of the 
outer shell as well as to accumulate into central 
lipid droplets [36]. CE molecules are the most 
hydrophobic and possess a high level of confor-
mational flexibility. It has been shown that CE is 
located in the central core of HDL [36]. BOC-
CE-OA molecules have a structure similar to CE 
but they are endowed with the capability to 
form intermolecular hydrogen bonds. 
The size of the LNPs with different core compo-
nents was determined by dynamic light scatter-
Figure 10. Fluorescent microscopy of CER-43 cells stained with (A) ICAM-1-LNP-Pyro- PtdEtn and (B) plain LNPs. 
CER-43 cells were stained with LNPs for 3 hr at 37°C. After washing the samples were used for microscopy on a 
wide field fluorescence microscope. The near-infrared fluorescence of the probes was excited by Xenon Lamp at 
620/60 nm and emission was collected with 700/75 nm band pass filter.
Core-based lipid nanoparticles
517 Am J Nucl Med Mol Imaging 2014;4(6):507-524
ing (Figure 4). All LNPs had the same shell com-
position but differ by core content. Fluorescent 
probes were excluded from the LNPs for these 
studies because the laser excitation wave-
length overlaps with the excitation wavelengths 
of the fluorescent lipid probes. As is evident 
from Figure 4, the size of the LNPs depends on 
core composition. The particles with cholester-
ol core had the largest size (up to 20 nm) pre-
sumably due to the intercalation of the choles-
terol molecule between the DSPE-PEG outer 
shell lipids [37]. When cholesterol oleate was 
used as a core constituent, the LNP size was 
decreased. LNPs containing cholesterol ester 
derivatives, BOC-CE-OA, had the smallest size 
with a narrow distribution pattern. 
LNPs core composition also influenced the par-
ticle shelf life. While the LNPs without core and 
LNPs with CE-OA core do not decay for at least 
4 weeks storage at 4°C, LNPs with BOC-CE-OA 
core are completely disassembled during this 
time with visible sign of lipid precipitation.
Attachment of protein ligands 
The LNP platform permits the conjugation of 
multiple ligands with the particles. The forma-
tion of multivalent nanoparticle conjugates 
allows the potential achievement of optimal 
performance for therapeutic and imaging appli-
cations and is especially important when weak 
ligand-receptor interactions are involved [27, 
38]. Herein, we employed two protein ligands, 
Intercellular Adhesion Molecule 1 (ICAM-1) and 
human leukocyte antigen A0201 (HLA-A2) 
associated with antigenic peptide, which have 
low intrinsic affinity to their corresponding cell 
surface receptors, αLβ2 integrin and T cell 
receptor (TCR). Both receptors form high den-
sity clusters on the leucocyte surface enhanc-
ing selectivity of nanoparticle targeting 
[39-42]. 
His6 tags were placed on the C-end of the ligand 
molecules to secure uniform positioning of the 
protein relative to the nanoparticle surface and 
guarantee productive interaction with corre-
sponding receptors on a cell surface. We previ-
ously successfully conjugated ICAM-1 and HLA-
A2 soluble molecules with lipid encapsulated 
quantum dots, and utilized the conjugates for 
specific staining of human T cell clones [23, 
43].
The conjugate formation was driven by metal-
affinity interaction between His6 tag of protein 
ligands and the Ni-NTA-moiety of the lipid shell. 
The ligand attachment to the LNPs was moni-
tored by agarose gel electrophoresis. The Cy5 
labeled proteins were mixed with the CE-OA-
LNPs at different ratios with the aim of achiev-
ing ligand saturation, and the mixtures were 
subjected to agarose gel electrophoresis. The 
amount of protein needed to saturate the LNPs 
was determined by agarose gel electrophore-
sis. The protein bands were visualized by dye 
adsorption (Figure 5A). It has previously been 
shown that the electrophoretic mobility of heav-
ily PEGylated nanoparticles are small or negli-
gible due to the thickness of the polymer coat-
ing and the consequent shielding of nanoparticle 
surface charge. Consistent with this, the LNPs 
conjugated with the ligands showed insignifi-
cant electrophoretic mobility compared with 
free protein. The insulation of the lipid head 
charge with PEG prevents movement of the 
conjugated LNPs while the negatively charged 
protein migrated toward the cathode. Saturation 
of the LNPs with protein was achieved when 15 
μg protein were mixed with 1 μl of LNPs suspen-
sion at 5 mM lipid concentration. After further 
increasing of the ligand amount in the mixture, 
the strong band of the free protein was 
observed (Figure 5A, third line).
Conjugate formation was confirmed by utilizing 
the Lipo Electrophoresis kit (Beckman Coulter) 
that enables the visualization of the lipid com-
ponent of the LNPs by the Paragon lipid stain. 
As is evident from Figure 5B lipid and protein 
staining were overlapped. 
It is important to confirm that conjugated lig- 
ands are active after association with LNPs. To 
demonstrate this, HLA-A2 protein was chosen 
as a targeting ligand. After loading with GL9 
peptide, the pMHC ligand was specifically rec-
ognized by T cell receptor on the surface of 
CER-43 T cells. It has been shown that soluble 
pMHC monomer is not stimulatory, and induc-
tion of TCR-mediated signaling requires TCR 
engagement by at least a bivalent pMHC ligand 
[44, 45]. Conjugation of the pMHC with 
nanoparticles results in the formation of multi-
valent pMHC ligands, whose recognition induc-
es an increase in intracellular Ca2+ concentra-
tion in T cells. This approach was successfully 
exploited in our previous work to monitor bind-
ing specificity and functionality of lipid encap-
sulated QD nanoparticles conjugated with GL9-
HLA-A2 [23, 43]. As is evident from Figure 6, 
Core-based lipid nanoparticles
518 Am J Nucl Med Mol Imaging 2014;4(6):507-524
the CE-OA-LNP-GL9-HLA-A2 conjugate induces 
an increase in intracellular calcium in T cells to 
a similar extent as the GL9-HLA-A2-QDs conju-
gate. In control experiments, the LNPs were not 
loaded with Ni2+ and consequently were inca-
pable to form conjugates with His6-tagged pro-
teins. The mixture of the unloaded LNPs and 
cognate GL9-HLA-A2 did not induce Ca2+ influx 
in the T cells (Figure 6). These results demon-
strate that LNPs can be easily conjugated with 
His6-containing proteins using incorporated 
Ni-NTA-DOGS lipids, and that the proteins retain 
their functional activity after association with 
LNPs.
Effect of the core on LNP shelf-life and stability 
at physiological temperature
Changing core lipid composition can affect the 
hydrophobic interaction in the LNPs interior 
altering the stability of the nanoparticles. To 
assay stability, the LNP-GL9-HLA-A2 conju-
gates were incubated in DPBS, for 3 hr at 37°C. 
We used LNPs containing CE-OA and BOC-CE-
OA molecules, which differ in structure only by 
the polar Boc moiety. Stability was compared 
by the functional calcium assay (Figure 7A and 
7B) or by measuring the binding ability of the 
conjugates (Figure 7C). Whereas the LNPs with 
the CE-OA core do not significantly change the 
magnitude of the Ca2+ flux in CER-43 cells after 
3 hours at 37°C, cells treated with LNPs with 
the BOC-CE-OA core demonstrated a decrease 
in the magnitude of the Ca2+ flux (Figure 7A). 
Moreover, LNPs with the CE-OA core effectively 
induced the CTL response even after 24-hour 
incubation at 37°C (Figure 7B). Assessment of 
the LNP-GL9-HLA-A2 conjugates binding con-
firms our initial results. These data indicates 
that LNPs with CE-OA core have improved sta-
bility in agreement with the shelf life measure-
ments of unconjugated LNPs. Thus, for all fur-
ther experiments LNPs with a CE-OA core were 
utilized. 
Interaction of the targeted Pyro-LNPs with 
specific cells in vitro 
To endow the targeted particles with NIR fluo-
rescent properties two different Pyro conju-
gates were used: (i) core targeted Pyro-CE-OA 
conjugate and (ii) shell targeted Pyro-PtdEtn 
conjugate. Pyro can form aggregates at high 
concentration, so based on our previous experi-
ence the amount of fluorescent lipid in the 
nanoparticle composition did not exceed 3% 
mol %. 
The LNPs were functionalized with ICAM-1 
adhesion molecules that recognized αLβ2 integ-
rin receptor (LFA-1). CER-43 human T cells over-
express LFA-1 on their cell surface. The LFA-1 
molecule contains a single divalent cation bind-
ing site, called the I domain [46]. Interaction of 
LFA-1 with ICAM-1 ligand depends on the pres-
ence of Mg2+ and Ca2+. As is evident from Figure 
8A, ICAM-1 loaded nanoparticles specifically 
interacted with the surface of CER43 cells in 
the presence of 1 mM Mg2+ and Ca2+ in the 
staining buffer. Removing the divalent cations 
from the buffer led to a decrease in this interac-
tion (Figure 8B). This demonstrates the speci-
ficity of ICAM-1-LNPs binding to the cell surface. 
Although the intrinsic affinity of the interaction 
between ICAM-1 molecules and their receptor 
is low [47], the staining was highly sensitive 
(Kavidity ~ 8 nM) presumably due to the multiva-
lent nature of ICAM-1-LNPs (Figure 8C). 
The amplitude of the fluorescence depends on 
the nature of Pyro-lipid conjugates. The cells 
incubated with ICAM-1-LNP-Pyro-PtdEtn had a 
higher mean fluorescence intensity (MFI)) rela-
tive to background (Figure 9A) than ICAM-1-
LNP-Pyro-CE-OA treated cells (Figure 9B). To 
understand better the difference in the LNPs 
containing different fluorescent conjugates we 
investigated changes of the cell MFI as function 
of time (Figure 9). As is evident from Figure 9C, 
the fluorescence of the cells incubated with 
ICAM-1-LNP-Pyro-PtdEtn dramatically increa- 
sed while fluorescence of the cells incubated 
with ICAM-1-LNPs-Pyro-CE-OA stayed constant 
(Figure 9D). This suggests that shell-associat-
ed fluorescent lipids can exchange with cell 
membrane lipids allowing accumulation of 
Pyro-PtdEtn conjugates in the cell membrane 
of target cells, thus increasing intensity of cell 
staining [48]. Pyro-CE-OA conjugate lipids on 
the other hand, have a low ability to accumulate 
in the cell membrane. Furthermore, after rele- 
asing the contents of endocytosed LNPs in the 
cytoplasm, Pyro-CE-OA conjugate lipids could 
self-quench due to aggregation in aqueous 
solution [49].
The conclusion is supported by analysis of fluo-
rescence images of CER-43 cells incubated 
with the ICAM-1-LNP-Pyro-PtdEtn at 37°C 
(Figure 10). Interaction of ICAM-1-LNP-Pyro-
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PtdEtn with the surface of CER-43 cells leads 
to accumulation of the fluorescent dye mostly 
in the cell membrane (Figure 10A). Binding of 
the untargeted LNPs to the CER-43 cells was 
not observed thus confirming the specificity of 
the process (Figure 10B). The intensity of the 
staining the LNPs increased with time (data not 
shown). Thus, the imaging data confirm that 
specific targeting of T cell surface with ICAM-1-
LNP-Pyro-PtdEtn lead to accumulation of Pyro-
PtdEtn conjugates in the cell membrane.
Discussion
We have recently developed a series of porphy-
rin-based NIR fluorescent probes, which are 
analogs of cell membrane lipids and have 
potential to be used as photodynamic therapy 
(PDT) agents [3, 5]. In previous studies lipo-
some formulations were employed for probe 
delivery, and the resulting unilamellar vesicles 
were utilized for imaging of tumors in a mouse 
model [4]. The phospholipid liposomes have a 
relatively large size (>70 nm) leading to their 
preferential accumulation in tumor perivascu-
lar space and little permeation into the tumor 
[50]. This is useful for NIR imaging purposes 
but less promising for PDT where the malignant 
cell bulk needs to be targeted. 
The main factors preventing formation of stable 
phospholipid liposomes of sub-70 nm size are 
membrane rigidity and edge tension [51]. To 
overcome this obstacle, we decided to utilize 
micelle structures spontaneously formed by 
PEGylated phospholipids in aqueous solutions 
[52]. Overall, the phospholipid PEGylated 
micelles are less stable in the blood circulation 
compared with phospholipid PEGylated lipo-
somes [53]. The influence of the phospholipid 
structure and size of the PEG head on the prop-
erties of the micelle are very well known and 
optimal shell phospholipid structure can be 
chosen for particular needs [54]. To tune the 
stability of the nanocarriers in blood circula-
tion, we introduced cholesterol or cholesterol 
esters into the LNPs core composition. The 
resulting particles have a micellar structure 
with significantly smaller size (<20 nm) com-
pared to the liposomes we utilized previously. 
Surprisingly, the size of the LNPs revealed a 
strong dependence on core lipids showing a dif-
ference of 2.5 fold between the smallest (BOC-
CE-OA) and the largest (cholesterol) core. The 
behavior of hydrophobic core components of 
different nature has been previously investigat-
ed for spheroidal high density lipoprotein (HDL) 
[36, 55]. The hydrophobic CE-OA molecules are 
located in the core of the HDL and have mini-
mal overlap with water, whereas most of the 
cholesterol is located just below the phospho-
lipids forming the outer layer with a small but 
significant concentration of cholesterol also 
found in the core of the HDL [36]. It is suggest-
ed that cholesterol molecules are able to inter-
calate between the alkyl chains of the outer 
phospholipids shell of LNPs while cholesterol 
oleate molecules concentrate mostly in the 
central part of the micelle, thus explaining the 
difference in the size of CE-OA or cholesterol 
containing LNPs. Intriguingly, the LNPs with the 
BOC-CE-OA core, which contains lipids with 
more a polar moiety than CE-OA, possess the 
smallest size. Presumably, the formation of the 
hydrogen bonds between the BOC-CE-OA mol-
ecules leads to more unfavorable entropy of 
the micelle self-assembly process and conse-
quently to destabilization of the particles.
Our results also showed that changes in the 
core lipids have a strong impact not only on size 
of the LNPs but also on their shelf-life and sta-
bility at physiological temperature. It has been 
shown that in vitro stability of micelles is 
inversely correlated with residency time of a 
lipid monomer in a micelle [56]. A highly hydro-
phobic micelle core provides a large activation 
barrier to monomer desorption from the micelle 
leading to great stability of the particles [56-
58]. Thus, the greater stability of the CE-OA 
containing LNPs might be explained by higher 
hydrophobicity of the CE-OA core forming mole-
cules compared with BOC-CE-OA lipids. The 
nanoparticle core hydrophobicity and/or the 
relative rigidity of the nanoparticle core have an 
important effect on blood residency time but 
the nature of the effect could be more complex 
in character than in a cellular free system [54]. 
Particularly, the size and rigidity of the LNPs 
should allow them to adapt to the size and 
shape of the fenestrations in leaky tumor vas-
cularity leading to a significant effect on parti-
cle accumulation in the solid tumor.
After reaching the tumor tissue, LNPs should 
have the ability to specifically deliver PDT 
agents to cancer cells leaving normal otherwise 
cells intact. To actively target unwanted cells 
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and to enhance probe delivery, the LNPs were 
functionalized with Ni-NTA containing lipids 
(DOGS-NiNTA), which allows protein ligands 
containing His6 tags to be conjugated without 
applying harsh conjugation chemistry. As expe- 
cted, after ligation with low affinity ligands 
(0.01-1 µM) the resulting multivalent LNPs spe-
cifically interacted with the receptors on the 
cell surface with high avidity. This data is in 
agreement with the results of several other 
groups that have utilized NTA containing nanoli-
poparticles for immobilization of His-tagged 
proteins [23, 43, 59-63].
Both NIR probes utilized in our study were 
based on Pyropheophorbide-a but differed by 
the nature of the conjugated lipid (phospholipid 
vs cholesterol oleate). Pyro conjugated with 
phospholipids shows better kinetics and a high-
er magnitude of cellular accumulation com-
pared with the cholesterol based probe. While 
phospholipids are the major constituent of all 
cell membranes, cholesterol esters are stored 
and transported largely in bulk lipid phases 
such as intracellular lipid storage droplets and 
serum lipoproteins [64]. The difference in kinet-
ics of the probes accumulation could be 
explained by the intrinsic ability of the Pyro-
PtdEtn probe to intercalate into the target cell 
membranes for producing signal. This localiza-
tion of Pyro-PtdEtn probe in the cellular mem-
brane is supported by fluorescent microscopy. 
Pyro-CE-OA conjugates have a higher chance to 
be delivered in cell cytoplasm. In aqueous solu-
tions Pyro and their conjugates with lipids can 
form aggregates resulting in fluorescent reab-
sorption and intermolecular quenching [4, 7]. 
The singlet oxygen quantum yields of aggregat-
ed species are lower than those of monomers, 
reducing their PDT efficiency. Thus, the Pyro-
PtdEtn probe has the ability to be a more potent 
imaging agent and photosynthesizer than Pyro-
CE-OA probe.
Conclusions and future perspective
The goal of this study was to develop an appro-
priate carrier for delivering of a hydrophobic 
NIR dye, i.e. pyropheophorbide a conjugated 
with a lipid, to the membrane of targeted cells. 
For this purpose, lipid-based nanoparticles 
with a core-shell structure were utilized. Cha-
nging the core composition allowed us to tune 
the LNP properties. In particular, the usage of a 
cholesterol oleate core improved the stability of 
the particles at physiological temperature and 
their shelf-life. The LNPs loaded with shell but 
not core targeted Pyro-conjugates revealed 
great ability to accumulate in the cell mem-
brane. These properties increase the potential 
of the probe for application in vivo as an imag-
ing and PDT agent. It is not clear at present 
what the impact of the in vivo environment will 
be on the LNPs targeting capability. To over-
come this obstacle, we have also developed a 
Pyro-based “smart” probe that possesses tar-
geting properties. The probe was constructed 
by conjugation of Pyro and a quencher (Black 
Hole Quencher 3) to a phosphatidylethanol-
amine backbone [3-5]. The probe is recognized 
and cleaved by phosphatidylcholine-specific 
phospholipase C, which shows enhanced accu-
mulation in different types of cancers [65-68]. 
Enzymatic cleavage dequenches the Pyro fluo-
rescence and restores the Pyro photoreactivity 
resulting in a pronounced NIR fluorescence sig-
nal recovery and photodynamic cytotoxicity. 
The developed LNPs are well suited to serve as 
an in vivo nanocarrier for this advanced “smart” 
probe. Furthermore, the lipid based nanoparti-
cles loaded with core will be tested as vehicles 
for targeted delivery of lipophilic fluorinated 
potential drugs and imaging agents that we 
have been developing in recent years [69- 
75]. 
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